Envafolimab Combined With Trifluridine/Tipiracil and Bevacizumab in the Treatment of Refractory mCRC. - Trial NCT06060704
Access comprehensive clinical trial information for NCT06060704 through Pure Global AI's free database. This Phase 2 trial is sponsored by The First Affiliated Hospital with Nanjing Medical University and is currently Recruiting. The study focuses on Metastatic Colorectal Cancer. Target enrollment is 33 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
The First Affiliated Hospital with Nanjing Medical University
Timeline & Enrollment
Phase 2
Nov 01, 2023
Sep 01, 2025
Primary Outcome
ORR๏ผObjective response rate๏ผ
Summary
The goal of this single-arm study is to evaluate the efficacy and safety of Envafolimab
 combined with Trifluridine/Tipiracil and Bevacizumab in the treatment of metastatic
 colorectal cancer patients who are refractory or intolerant to standard therapy.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06060704
Non-Device Trial